|Bid||6.56 x 0|
|Ask||6.90 x 0|
|Day's range||6.74 - 6.80|
|52-week range||5.18 - 10.75|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||0.20 (2.91%)|
|1y target est||7.80|
ABANO TERME, Italy--(BUSINESSWIRE)-- Poster Title: “Hyaluronan Derivative Hymovis ® Increases Cartilage Volume and Type II Collagen Turnover in Osteoarthritis Knee: Data from MOKHA ( M RI, Bi O markers, ...
Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA Inc., are projecting continued growth in 2017. The global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021, according to a research study by RnR Market Research1. Fidia Farmaceutici S.p.A. now leads the orthopedic biomaterials market in Europe after increasing its market share over the past few years.